Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer?
Pisters
Peter W T
PW
Evans
Douglas B
DB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005544:Forecasting; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D009367:Neoplasm Staging; D010180:Pancreatectomy / Q000379:methods; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012106:Research; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016019:Survival Analysis
D016898:Interferon-alpha; D002945:Cisplatin; D005472:Fluorouracil